Celadon Pharmaceuticals Plc (CEL.L) Comparison with companies in other sectors?

Celadon Pharmaceuticals Plc has a share price of 68.85M. You can analyze Celadon Pharmaceuticals Plc (CEL.L) competitors across different market sectors through stock heatmaps.

What are CEL.L's NET and operating margins?

Celadon Pharmaceuticals Plc (CEL.L) operating margin is around 23.73, and net profit margin is approximately -39.51 as of the latest reports.

In what way does CEL.L's earnings per share (EPS) trend reflect its financial momentum?

Celadon Pharmaceuticals Plc (CEL.L) EPS is -0.08 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Celadon Pharmaceuticals Plc is -1.67, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Celadon Pharmaceuticals Plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Celadon Pharmaceuticals Plc like P/E which is -2.27, P/B which is 3.56, and PEG which is -6.26. Compare them with sector averages to evaluate if the stock is priced fairly.

Celadon Pharmaceuticals Plc

CEL.L•LSE

Healthcare

Drug Manufacturers - Specialty & Generic

£13.40

£0.00(0.00%)

Celadon Pharmaceuticals Plc (CEL.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.08

P/E Ratio

-1.67

ROE

-1.43%

Net Margin

-39.51%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$9.23M

Shares OutstandingTotal number of shares issued

$68.85M

Book Value/ShareNet worth per share

$0.04

Revenue/ShareAnnual revenue per share

$0.001

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.08

Net MarginNet income as percentage of revenue

-3950.78%

Operating MarginOperating income as percentage of revenue

2372.54%

ROEReturn on shareholders' equity

-142.65%

ROAReturn on total assets

-45.05%

ROCEReturn on capital employed

30.19%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.06

Cash/ShareCash and equivalents per share

$0.00

FCF YieldFree cash flow as percentage of market cap

-45.40%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CEL.LFinancial Ratios Analysis details for CEL.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CEL.LSector Benchmarking details for CEL.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Celadon Pharmaceuticals Plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Celadon Pharmaceuticals Plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Celadon Pharmaceuticals Plc's unique business strengths and challenges.

Key Financial Metrics for Celadon Pharmaceuticals Plc

For Celadon Pharmaceuticals Plc, essential financial indicators include EPS -0.08, PE -1.67, and ROE -1.43. These key ratios reveal insights into Celadon Pharmaceuticals Plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Celadon Pharmaceuticals Plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Celadon Pharmaceuticals Plc

Metrics like Net Margin -3950.78% and ROA -45.05% shed light on how well Celadon Pharmaceuticals Plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Celadon Pharmaceuticals Plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Celadon Pharmaceuticals Plc

Using ratios such as P/B Ratio 3.56 and PEG Ratio -6.26, investors can assess whether Celadon Pharmaceuticals Plc is appropriately valued based on its financials and growth potential. These figures, combined with Celadon Pharmaceuticals Plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Celadon Pharmaceuticals Plc

Financial health indicators, such as Debt/Equity Ratio 1.97 and Cash Flow $-0.06, provide a snapshot of Celadon Pharmaceuticals Plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Celadon Pharmaceuticals Plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Celadon Pharmaceuticals Plc

Investing in Celadon Pharmaceuticals Plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Celadon Pharmaceuticals Plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;